A single investor, Heights Capital, bought 50 million shares and pre-funded warrants at $40 and received 100 million seven-year warrants. The structure repeats a deal with the same buyer a year ago, whose warrants are now far out of the money.
IonQ priced a $2 billion sale on Wednesday at a price above where its stock had closed. The market's verdict was that the buyer got the better deal.
The quantum computing company priced a sale of 20.5 million shares and 29.5 million pre-funded warrants at $40.00 each to one investor, Heights Capital, before the open. That price was about 15% above Tuesday's close of $34.73. Heights also received 100 million Series C warrants, exercisable for seven years at $69.46, exactly double Tuesday's close. IonQ expects net proceeds of about $1.99 billion when the sale settles on Oct. 16.
By about 1:40 p.m. Eastern, IonQ shares were down 9.4% at $31.45, about 21% below the price Heights paid.
Why a premium can still be dilutive
The headline premium leaves out half the package. For every share or pre-funded warrant Heights bought, it received two additional long-dated warrants. A seven-year option on a stock this volatile carries real value even when the strike is well above the current price. Counting that value, the effective price Heights paid per share is meaningfully below $40.
The share count shows the scale. IonQ had about 408.9 million shares outstanding. The deal lifts that to about 429.4 million immediately and to about 558.9 million if every pre-funded and Series C warrant is exercised, an increase of roughly 37% from the starting base.
The precedent
The deal mirrors one IonQ struck with Heights in October 2025, priced at $93 a share with warrants at $155. With the stock now near $31, those earlier warrants are about 80% out of the money. The repeat transaction suggests IonQ values speed and size of funding from a single counterparty over a broader marketed offering.
Relative performance
Other quantum stocks also fell. Rigetti Computing, D-Wave Quantum and Quantum Computing Inc. were down an average of about 6.9% at the same time, on a day when the Nasdaq Composite fell about 2%. IonQ's extra decline of roughly 2.6 percentage points is a rough measure of how the market priced the deal itself.
Market implications
The case for the deal is balance-sheet strength. Two billion dollars of new capital lets IonQ fund research, acquisitions and manufacturing without returning to the market soon, in a sector where customers weigh supplier staying power.
The case against is cost. Shareholders face up to 150 million new shares, and the warrant coverage transfers much of the upside to one investor. With the stock well below the deal price, Heights could also hedge its exposure, which could weigh on the shares in coming sessions.
What to watch
The final prospectus supplement for the use of proceeds, trading volume as Heights' shares settle, and whether IonQ announces acquisitions that would explain the size of the raise.